Sutro Biopharma Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
304
- Stock Symbol
-
STRO
- Investments
-
1
- Share Price
-
$3.56
- (As of Monday Closing)
Sutro Biopharma General Information
Description
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Contact Information
Website
www.sutrobio.comCorporate Office
- 111 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Corporate Office
- 111 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Sutro Biopharma Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.56 | $3.61 | $2.00 - $6.13 | $291M | 82M | 674K | -$1.78 |
Sutro Biopharma Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (45,491) | (55,487) | 193,106 | 517,284 |
| Revenue | 169,359 | 153,731 | 67,772 | 61,880 |
| EBITDA | (82,042) | (72,545) | (111,123) | (98,134) |
| Net Income | (124,450) | (106,793) | (119,204) | (105,538) |
| Total Assets | 489,043 | 470,736 | 406,944 | 341,408 |
| Total Debt | 26,526 | 33,635 | 50,430 | 57,374 |
Sutro Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sutro Biopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Sutro Biopharma Comparisons
Industry
Financing
Details
Sutro Biopharma Competitors (121)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mersana Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Inhibrx | Formerly VC-backed | La Jolla, CA | ||||
| iTeos Therapeutics | Formerly VC-backed | Gosselies, Belgium | ||||
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Arcus Biosciences | Formerly VC-backed | Hayward, CA |
Sutro Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sutro Biopharma Patents
Sutro Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240148890-A1 | Anti-folate receptor conjugate therapy for cancer treatment | Pending | 21-Oct-2022 | ||
| US-20240124585-A1 | Anti-cd3 antibodies, compositions comprising anti-cd3 antibodies and methods of making and using anti-cd3 antibodies | Pending | 29-Sep-2022 | ||
| US-20240043895-A1 | Spray dried extract | Pending | 08-Aug-2022 | ||
| US-20240058467-A1 | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates | Pending | 30-Jun-2022 | ||
| US-20240058465-A1 | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates | Pending | 30-Jun-2022 | A61K47/6849 |
Sutro Biopharma Executive Team (35)
| Name | Title | Board Seat |
|---|---|---|
| William Newell JD | Chief Executive Officer & Board Member | |
| Jane Chung | Chief Commercial Officer | |
| Edward Albini | Chief Financial Officer | |
| Hans-Peter Gerber Ph.D | Chief Scientific Officer | |
| Barbara Leyman Ph.D | Chief Business Development Officer |
Sutro Biopharma Board Members (19)
| Name | Representing | Role | Since |
|---|---|---|---|
| Connie Matsui | Self | Chairman & Board Member | |
| Daniel Petree JD | Self | Board Member | |
| James Panek | Self | Board Member | |
| John Freund MD | Skyline Ventures | Board Member | |
| Jon Wigginton | Self | Board Member |
Sutro Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sutro Biopharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sutro Biopharma Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vaxcyte | 23-Jul-2015 | Drug Discovery |
Sutro Biopharma ESG
Risk Overview
Risk Rating
Updated February, 03, 2023
33.35 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Pharmaceuticals
Industry
of 909
Rank
Percentile
Pharmaceuticals
Subindustry
of 446
Rank
Percentile
Sutro Biopharma Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Vaxcyte | 23-Jul-2015 | Completed |
|
Sutro Biopharma FAQs
-
When was Sutro Biopharma founded?
Sutro Biopharma was founded in 2003.
-
Who is the founder of Sutro Biopharma?
James Swartz Ph.D is the founder of Sutro Biopharma.
-
Who is the CEO of Sutro Biopharma?
William Newell JD is the CEO of Sutro Biopharma.
-
Where is Sutro Biopharma headquartered?
Sutro Biopharma is headquartered in South San Francisco, CA.
-
What is the size of Sutro Biopharma?
Sutro Biopharma has 304 total employees.
-
What industry is Sutro Biopharma in?
Sutro Biopharma’s primary industry is Drug Delivery.
-
Is Sutro Biopharma a private or public company?
Sutro Biopharma is a Public company.
-
What is Sutro Biopharma’s stock symbol?
The ticker symbol for Sutro Biopharma is STRO.
-
What is the current stock price of Sutro Biopharma?
As of 07-Oct-2024 the stock price of Sutro Biopharma is $3.56.
-
What is the current market cap of Sutro Biopharma?
The current market capitalization of Sutro Biopharma is $291M.
-
What is Sutro Biopharma’s current revenue?
The trailing twelve month revenue for Sutro Biopharma is $169M.
-
Who are Sutro Biopharma’s competitors?
Mersana Therapeutics, Inhibrx, iTeos Therapeutics, Fate Therapeutics, and Arcus Biosciences are some of the 121 competitors of Sutro Biopharma.
-
What is Sutro Biopharma’s annual earnings per share (EPS)?
Sutro Biopharma’s EPS for 12 months was -$1.78.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
